Home Articles List Article Information
ALEXMED ePosters
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
El Ghandour, A., Zaki, N., Helmy, M., Nadwan, E., Donia, H., Kamel, A. (2021). IMMATURE PLATELET FRACTION AS A BIOMARKER OF SEPSIS IN ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING CHEMOTHERAPY. ALEXMED ePosters, 3(4), 103-104. doi: 10.21608/alexpo.2021.110355.1326
Ashraf Hussein El Ghandour; Nadia El Sayed Zaki; Mona Wagdy Helmy; Eman Attia Nadwan; Hanaa Donia; Alaa AbdElhady Mohamed Kamel. "IMMATURE PLATELET FRACTION AS A BIOMARKER OF SEPSIS IN ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING CHEMOTHERAPY". ALEXMED ePosters, 3, 4, 2021, 103-104. doi: 10.21608/alexpo.2021.110355.1326
El Ghandour, A., Zaki, N., Helmy, M., Nadwan, E., Donia, H., Kamel, A. (2021). 'IMMATURE PLATELET FRACTION AS A BIOMARKER OF SEPSIS IN ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING CHEMOTHERAPY', ALEXMED ePosters, 3(4), pp. 103-104. doi: 10.21608/alexpo.2021.110355.1326
El Ghandour, A., Zaki, N., Helmy, M., Nadwan, E., Donia, H., Kamel, A. IMMATURE PLATELET FRACTION AS A BIOMARKER OF SEPSIS IN ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING CHEMOTHERAPY. ALEXMED ePosters, 2021; 3(4): 103-104. doi: 10.21608/alexpo.2021.110355.1326

IMMATURE PLATELET FRACTION AS A BIOMARKER OF SEPSIS IN ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING CHEMOTHERAPY

Article 1, Volume 3, Issue 4, December 2021, Page 103-104  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2021.110355.1326
View on SCiNiTO View on SCiNiTO
Authors
Ashraf Hussein El Ghandour1; Nadia El Sayed Zaki1; Mona Wagdy Helmy2; Eman Attia Nadwan1; Hanaa Donia3; Alaa AbdElhady Mohamed Kamel email 1
1Department of Internal Medicine (Hematology Unit), Faculty of Medicine , Alexandria University
2Department of Clinical and Chemical Pathology, Faculty of Medicine Alexandria University
3Department of Clinical Pathology, Faculty of Medicine , Alexandria University
Abstract
Acute myeloid leukemia (AML) characterized by clonal myeloid precursor proliferation with decreased differentiation into more mature cells which lead to an accumulation of leukemic blasts in the bone marrow, peripheral blood, and occasionally in other tissues and the development of normal red blood cells , platelets and mature granulocytes is decreasing.
Febrile neutropenia is a medical emergency that requires urgent evaluation, the timely administration of empiric broad-spectrum antimicrobials, and careful monitoring to optimize patient outcomes and diminish the risk of complications.
A new definition of sepsis, termed (Sepsis-3) as life-threatening organ dysfunction caused by a dysregulated host response to infection.
Recently, non-invasive assessment of platelet turnover has been performed by measuring the immature platelet fraction (IPF). The percentage of reticulated platelets indicates the degree of platelets damage and the generation of platelets in bone marrow.
AIM OF THE WORK
To evaluate the immature platelet fraction in acute myeloid leukemia patients receiving chemotherapy as a predictor of onset of sepsis by comparing it to C reactive protein and serum ferritin.
Keywords
Acute myeloid leukemia (AML); Sepsis-3; IMMATURE PLATELET FRACTION
Supplementary Files
Statistics
Article View: 227